Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer

D. Scott Lind, Rebecca Minter, Barbara Steinbach, Patricia Abbitt, Linda Lanier, Linda Haigh, J. Nicholas Vauthey, Millie Russin, Raymond Hackett, Edward M. Copeland

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The management of patients with mammographic abnormalities is rapidly shifting from needle-localized surgical biopsy (NLB) to stereotactic core biopsy (SCB). The precise role of SCB in the management of nonpalpable breast cancer remains to be defined. The purpose of this study was to compare SCB to NLB in the diagnosis of mammographically detected breast cancer in women who underwent breast-conserving surgery. The records of all patients with nonpalpable breast cancer who underwent breast-conserving surgery from 1/1/95 to 6/1/97 were analyzed with respect to method of diagnosis, time interval from detection to diagnosis and breast-conserving surgery, volume of breast tissue excised, margin status and reexcision rate, number of surgical procedures, and total charges and costs per patient. During a 30-month period, 117 patients with nonpalpable breast cancer underwent breast- conserving surgery. The diagnosis was made by NLB in 69 patients and SCB in 48 patients. The time from detection to diagnosis and breast-conserving surgery was 1.7 ± 0.5 and 8.1 ± 1.2 days for SCB patients and 6.8 ± 1.3 and 16.9 ± 2.3 days for NLB patients (P 0.01). The volume of breast tissue removed was 117.9 ± 5.6 cm3 for SCB patients versus 75.2 ± 2.9 cm3 for NLB patients (P < 0.01). Three SCB patients (6%) had positive margins, while 38 NLB patients (55%) had positive margins (P < 0.01). Only 1 SCB patient (2%) was reexcised, while 34 NLB patients (50%) were reexcised (P 0.01). Eighty-nine percent of SCB patients had a single surgical procedure compared to 39% of NLB patients (P < 0.001). Patients who underwent SCB had reduced total charges and total costs per patient compared to NLB patients ($11,700 ± $554 and $3537 ± $167 per SCB patient versus $15,654 ± $706 and $4853 ± $198 per NLB patient, P < 0.0001). Stereotactic core biopsy shortens the time from detection at mammography to diagnosis and breast-conserving therapy, permits appropriate discussion of treatment alternatives, reduces the positive margin rate and reexcision rate, and may represent a significant cost savings in the management of nonpalpable breast cancer.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalJournal of Surgical Research
Volume78
Issue number1
DOIs
StatePublished - Jul 15 1998

Fingerprint

Biopsy
Costs and Cost Analysis
Neoplasms
Needles
Segmental Mastectomy
Breast Neoplasms
Breast
Large-Core Needle Biopsy
Cost Savings
Mammography

Keywords

  • Breast cancer
  • Cost
  • Reexcision
  • Stereotactic biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Lind, D. S., Minter, R., Steinbach, B., Abbitt, P., Lanier, L., Haigh, L., ... Copeland, E. M. (1998). Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer. Journal of Surgical Research, 78(1), 23-26. https://doi.org/10.1006/jsre.1998.5380

Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer. / Lind, D. Scott; Minter, Rebecca; Steinbach, Barbara; Abbitt, Patricia; Lanier, Linda; Haigh, Linda; Vauthey, J. Nicholas; Russin, Millie; Hackett, Raymond; Copeland, Edward M.

In: Journal of Surgical Research, Vol. 78, No. 1, 15.07.1998, p. 23-26.

Research output: Contribution to journalArticle

Lind, DS, Minter, R, Steinbach, B, Abbitt, P, Lanier, L, Haigh, L, Vauthey, JN, Russin, M, Hackett, R & Copeland, EM 1998, 'Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer', Journal of Surgical Research, vol. 78, no. 1, pp. 23-26. https://doi.org/10.1006/jsre.1998.5380
Lind, D. Scott ; Minter, Rebecca ; Steinbach, Barbara ; Abbitt, Patricia ; Lanier, Linda ; Haigh, Linda ; Vauthey, J. Nicholas ; Russin, Millie ; Hackett, Raymond ; Copeland, Edward M. / Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer. In: Journal of Surgical Research. 1998 ; Vol. 78, No. 1. pp. 23-26.
@article{f58473512a024ff89fdda5a65be8ad61,
title = "Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer",
abstract = "The management of patients with mammographic abnormalities is rapidly shifting from needle-localized surgical biopsy (NLB) to stereotactic core biopsy (SCB). The precise role of SCB in the management of nonpalpable breast cancer remains to be defined. The purpose of this study was to compare SCB to NLB in the diagnosis of mammographically detected breast cancer in women who underwent breast-conserving surgery. The records of all patients with nonpalpable breast cancer who underwent breast-conserving surgery from 1/1/95 to 6/1/97 were analyzed with respect to method of diagnosis, time interval from detection to diagnosis and breast-conserving surgery, volume of breast tissue excised, margin status and reexcision rate, number of surgical procedures, and total charges and costs per patient. During a 30-month period, 117 patients with nonpalpable breast cancer underwent breast- conserving surgery. The diagnosis was made by NLB in 69 patients and SCB in 48 patients. The time from detection to diagnosis and breast-conserving surgery was 1.7 ± 0.5 and 8.1 ± 1.2 days for SCB patients and 6.8 ± 1.3 and 16.9 ± 2.3 days for NLB patients (P 0.01). The volume of breast tissue removed was 117.9 ± 5.6 cm3 for SCB patients versus 75.2 ± 2.9 cm3 for NLB patients (P < 0.01). Three SCB patients (6{\%}) had positive margins, while 38 NLB patients (55{\%}) had positive margins (P < 0.01). Only 1 SCB patient (2{\%}) was reexcised, while 34 NLB patients (50{\%}) were reexcised (P 0.01). Eighty-nine percent of SCB patients had a single surgical procedure compared to 39{\%} of NLB patients (P < 0.001). Patients who underwent SCB had reduced total charges and total costs per patient compared to NLB patients ($11,700 ± $554 and $3537 ± $167 per SCB patient versus $15,654 ± $706 and $4853 ± $198 per NLB patient, P < 0.0001). Stereotactic core biopsy shortens the time from detection at mammography to diagnosis and breast-conserving therapy, permits appropriate discussion of treatment alternatives, reduces the positive margin rate and reexcision rate, and may represent a significant cost savings in the management of nonpalpable breast cancer.",
keywords = "Breast cancer, Cost, Reexcision, Stereotactic biopsy",
author = "Lind, {D. Scott} and Rebecca Minter and Barbara Steinbach and Patricia Abbitt and Linda Lanier and Linda Haigh and Vauthey, {J. Nicholas} and Millie Russin and Raymond Hackett and Copeland, {Edward M.}",
year = "1998",
month = "7",
day = "15",
doi = "10.1006/jsre.1998.5380",
language = "English (US)",
volume = "78",
pages = "23--26",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer

AU - Lind, D. Scott

AU - Minter, Rebecca

AU - Steinbach, Barbara

AU - Abbitt, Patricia

AU - Lanier, Linda

AU - Haigh, Linda

AU - Vauthey, J. Nicholas

AU - Russin, Millie

AU - Hackett, Raymond

AU - Copeland, Edward M.

PY - 1998/7/15

Y1 - 1998/7/15

N2 - The management of patients with mammographic abnormalities is rapidly shifting from needle-localized surgical biopsy (NLB) to stereotactic core biopsy (SCB). The precise role of SCB in the management of nonpalpable breast cancer remains to be defined. The purpose of this study was to compare SCB to NLB in the diagnosis of mammographically detected breast cancer in women who underwent breast-conserving surgery. The records of all patients with nonpalpable breast cancer who underwent breast-conserving surgery from 1/1/95 to 6/1/97 were analyzed with respect to method of diagnosis, time interval from detection to diagnosis and breast-conserving surgery, volume of breast tissue excised, margin status and reexcision rate, number of surgical procedures, and total charges and costs per patient. During a 30-month period, 117 patients with nonpalpable breast cancer underwent breast- conserving surgery. The diagnosis was made by NLB in 69 patients and SCB in 48 patients. The time from detection to diagnosis and breast-conserving surgery was 1.7 ± 0.5 and 8.1 ± 1.2 days for SCB patients and 6.8 ± 1.3 and 16.9 ± 2.3 days for NLB patients (P 0.01). The volume of breast tissue removed was 117.9 ± 5.6 cm3 for SCB patients versus 75.2 ± 2.9 cm3 for NLB patients (P < 0.01). Three SCB patients (6%) had positive margins, while 38 NLB patients (55%) had positive margins (P < 0.01). Only 1 SCB patient (2%) was reexcised, while 34 NLB patients (50%) were reexcised (P 0.01). Eighty-nine percent of SCB patients had a single surgical procedure compared to 39% of NLB patients (P < 0.001). Patients who underwent SCB had reduced total charges and total costs per patient compared to NLB patients ($11,700 ± $554 and $3537 ± $167 per SCB patient versus $15,654 ± $706 and $4853 ± $198 per NLB patient, P < 0.0001). Stereotactic core biopsy shortens the time from detection at mammography to diagnosis and breast-conserving therapy, permits appropriate discussion of treatment alternatives, reduces the positive margin rate and reexcision rate, and may represent a significant cost savings in the management of nonpalpable breast cancer.

AB - The management of patients with mammographic abnormalities is rapidly shifting from needle-localized surgical biopsy (NLB) to stereotactic core biopsy (SCB). The precise role of SCB in the management of nonpalpable breast cancer remains to be defined. The purpose of this study was to compare SCB to NLB in the diagnosis of mammographically detected breast cancer in women who underwent breast-conserving surgery. The records of all patients with nonpalpable breast cancer who underwent breast-conserving surgery from 1/1/95 to 6/1/97 were analyzed with respect to method of diagnosis, time interval from detection to diagnosis and breast-conserving surgery, volume of breast tissue excised, margin status and reexcision rate, number of surgical procedures, and total charges and costs per patient. During a 30-month period, 117 patients with nonpalpable breast cancer underwent breast- conserving surgery. The diagnosis was made by NLB in 69 patients and SCB in 48 patients. The time from detection to diagnosis and breast-conserving surgery was 1.7 ± 0.5 and 8.1 ± 1.2 days for SCB patients and 6.8 ± 1.3 and 16.9 ± 2.3 days for NLB patients (P 0.01). The volume of breast tissue removed was 117.9 ± 5.6 cm3 for SCB patients versus 75.2 ± 2.9 cm3 for NLB patients (P < 0.01). Three SCB patients (6%) had positive margins, while 38 NLB patients (55%) had positive margins (P < 0.01). Only 1 SCB patient (2%) was reexcised, while 34 NLB patients (50%) were reexcised (P 0.01). Eighty-nine percent of SCB patients had a single surgical procedure compared to 39% of NLB patients (P < 0.001). Patients who underwent SCB had reduced total charges and total costs per patient compared to NLB patients ($11,700 ± $554 and $3537 ± $167 per SCB patient versus $15,654 ± $706 and $4853 ± $198 per NLB patient, P < 0.0001). Stereotactic core biopsy shortens the time from detection at mammography to diagnosis and breast-conserving therapy, permits appropriate discussion of treatment alternatives, reduces the positive margin rate and reexcision rate, and may represent a significant cost savings in the management of nonpalpable breast cancer.

KW - Breast cancer

KW - Cost

KW - Reexcision

KW - Stereotactic biopsy

UR - http://www.scopus.com/inward/record.url?scp=0032527409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032527409&partnerID=8YFLogxK

U2 - 10.1006/jsre.1998.5380

DO - 10.1006/jsre.1998.5380

M3 - Article

C2 - 9733612

AN - SCOPUS:0032527409

VL - 78

SP - 23

EP - 26

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -